An in-silico approach to find a peptidomimetic targeting extracellular domain of HER3 from a HER3 Nanobody

Pourhashem, Zeinab; Mehrpouya, Masoumeh; Yardehnavi, Najmeh; Eslamparast, Ameneh; Kazemi‐Lomedasht, Fatemeh

doi:10.1016/j.compbiolchem.2017.02.001

Cited by 3 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an additional study, a mimotope was extracted from tocilizumab which could induce dual humoral and cellular responses of the immune system 49 . Pourhashem et al also designed a mimotope against HER3 using in silico studies, but not fully characterised and requiring further in vitro and in vivo experiments 24 .…”

Section: Discussionmentioning

confidence: 99%

“…Pourhashem et al. also designed a mimotope against HER3 using in silico studies, but not fully characterised and requiring further in vitro and in vivo experiments 24 .…”

Section: Discussionmentioning

confidence: 99%

“…Mimotopes represent new approaches in the treatment of human disorders such as cancer 25 . In 2017, Pourhashem et al designed and produced a peptidomimetic (named HER3) from its nanobody 24 . Mimotopes have many advantages such as an enhanced stability and a possible large-scale production.…”

Section: Introductionmentioning

confidence: 99%

“…Some peptide-based drugs have caught particular attention because of their abilities to ‘compensate’ therapeutic failings, as well as their small sizes and relative accessibility 22 . The mimotopes or peptidomimetics are small peptides that are recognised by the human immune system, and which possess some ‘key’ structural features resembling those of the antibody binding sites 23 , 24 . The mimotopes are peptides ‘mimicking’ proteins.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis

Karami

Sabatier

Behdani

et al. 2020

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Vascular Endothelial Growth Factor (VEGF) promotes angiogenesis in tumours of various cancers. Monoclonal antibodies and nanobodies are one of the potent agents in the treatment of cancer. Due to their high costs, researchers are considering to design and produce peptides as a substitute approach in recent years. The aim of the current study was designing a mimotope against VEGF and evaluate its effects on cell proliferation and tube formation in the HUVEC cell line. For this, a peptide was designed against VEGF and chemically produced. The effects of synthetic peptide and nanobody on the inhibition of proliferation of HUVEC cells were examined using MTT and tube formation assays. The data indicate that the peptide was able to significantly inhibit both HUVEC cell proliferation and tube formation through inhibition of VEGF, highlighting the potential of peptides as a 'novel' class of candidate drugs to inhibit angiogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Pourhashem et al. also designed a mimotope against HER3 using in silico studies, but not fully characterised and requiring further in vitro and in vivo experiments 24 .…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis

Karami

Sabatier

Behdani

et al. 2020

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…considered the complementarity-determining region 3 (CDR3) domain of HER3 nanobody as a mimicking peptide using bioinformatics studies. The resulted CDR3 fragment of the HER3 nanobody has a similar binding affinity to the HER3 receptor when compared to the full HER3 nanobody ( 23 ). In another study, Yang et al .…”

Section: Therapeutic Peptides Derived From Nanobodies and Mimotopesmentioning

confidence: 99%

Anti-angiogenic peptides application in cancer therapy; a review

Shoari

Khodabakhsh

Cohan

et al. 2021

Research in Pharmaceutical Sciences

View full text Add to dashboard Cite

Cancer is a disease advanced via surplus angiogenesis. The development of new anti-angiogenic therapeutic agents with more efficacy and fewer side effects is still quite necessary. Conventional therapies saving the life of many cancer patients but due to drug resistance and lack of specificity utilizing these methods is faced with limits. Recently, new therapeutic agents have been developed and used to treat cancers such as scaffold proteins, monoclonal antibodies, tyrosine kinase inhibitors, and peptides. In antiangiogenic drug development, anti-angiogenic peptides design is a significant aim. Peptides have developed as substantial therapeutics that are being carefully investigated in angiogenesis-dependent diseases because of their high penetrating rate into the cancer cells, high specificity, and low toxicity. In this review, we focus on anti-angiogenic peptides in the field of cancer therapy that are designed, screened, or derived from nanobodies, mimotopes, phage displays, and natural resources.

show abstract